Combating Methotrexate Resistance in Cancer Treatment: A Review on Navigating Pathways and Enhancing Its Efficacy With Fat‐Soluble Vitamins
Scientifica · 2025-01 · 2025 (1)
DOI: 10.1155/sci5/8259470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Scientifica, online erschienen am 16.04.2025. Verfasst von Muhsina Kakkadath und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methotrexate (MTX), a potent analogue and antagonist of folic acid, is a first‐line treatment for rheumatoid arthritis, IBD and cancer. The development of MTX resistance contributes to the reduced efficacy and development of adverse reactions, forcing clinicians to withdraw treatment early. This drawback requires combinational approaches to combat the resistance and enhance the efficacy and safety of MTX. To provide a brief overview of MTX resistance and strategies to mitigate its aftereffects in cancer therapy, a literature‐based search was conducted using keywords such as cancer pathology, MTX mechanism and resistance, S100A4, folate uptake, folate efflux, P‐glycoprotein, beta‐catenin and anticancer properties of Vitamins A, D, E and K. Investigations encompassing in vitro studies, in vivo studies and clinical trials were reviewed to identify the mechanisms of resistance induced by MTX and the potential benefits of coadministering fat‐soluble vitamins with existing anticancer drugs. Derivates of Vitamin A could target cancer stem cells and increase chemotherapy sensitivity in non–small cell lung cancer. Similarly, calcitriol and cytotoxic medications exhibit additive or synergistic effects. Existing research revealed that fat‐soluble vitamins can inhibit drug transporters, such as P‐glycoprotein, which inhibit drug efflux, improving chemotherapy efficacy in cancer. As personalised medicine continues to evolve, incorporating combination approaches with MTX and fat‐soluble vitamins holds promise for enhancing treatment efficacy, which can counteract MTX resistance via multiple pathways and improve the safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India.
- Graduate Institute of Medicine, Yuan Ze University, Taoyuan 32003, Taiwan.
ORCID-Profile: Muhsina Kakkadath, S K Kanthlal, Khan Sharun
Zitieren
APA
Kakkadath, M., Naidu, D., Kanthlal, S. K., & Sharun, K. (2025). Combating Methotrexate Resistance in Cancer Treatment: A Review on Navigating Pathways and Enhancing Its Efficacy With Fat‐Soluble Vitamins. Scientifica, 2025(1). https://doi.org/10.1155/sci5/8259470
Vancouver
Kakkadath M, Naidu D, Kanthlal SK, Sharun K. Combating Methotrexate Resistance in Cancer Treatment: A Review on Navigating Pathways and Enhancing Its Efficacy With Fat‐Soluble Vitamins. Scientifica. 2025;2025(1). doi:10.1155/sci5/8259470
BibTeX
@article{Kakkadath2025,
author = {Kakkadath, Muhsina and Naidu, Disha and Kanthlal, S K and Sharun, Khan},
title = {Combating Methotrexate Resistance in Cancer Treatment: A Review on Navigating Pathways and Enhancing Its Efficacy With Fat‐Soluble Vitamins},
journal = {Scientifica},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/sci5/8259470}
}
EUVIMED